Latest News - Imprimis Pharmaceuticals

Tuesday, January 30, 2018 | Product Releases, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs on FDA’s Drug Shortage List

Imprimis Pharmaceuticals announced that it is dispensing preservative-free dorzolamide and a preservative-free dorzolamide/timolol formulation after dorzolamide and the commercial products, Cosopt and…

Read the full story

Wednesday, January 24, 2018 | Miscellaneous, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals is Issued DEA Manufacturer Certificate for its 503B Outsourcing Facility

Imprimis Pharmaceuticals announced that following inspection by the US Drug Enforcement Administration, its New Jersey FDA-registered outsourcing facility has been issued a DEA Manufacturer Controlled…

Read the full story

Wednesday, January 17, 2018 | Dry Eye, Allergan, Imprimis Pharmaceuticals

FDA Issues Warning Letter to Imprimis for False and Misleading Claims

The FDA has issued a warning letter to Imprimis Pharmaceuticals, claiming the maker of compounded drugs made false or misleading claims about its products. The FDA stated that Imprimis made misleading…

Read the full story

Tuesday, October 24, 2017 | Product Releases, Imprimis Pharmaceuticals

Imprimis Launches Surface Pharmaceuticals Subsidiary

Imprimis Pharmaceuticals announced it has formed a subsidiary, Surface Pharmaceuticals, intended to advance treatments for ocular surface diseases by seeking FDA approval for three drug candidates for…

Read the full story

Thursday, October 19, 2017 | Dry Eye, Product Releases, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals to Offer Compounded Cyclosporine

Imprimis Pharmaceuticals announced it is making compounded cyclosporine-based formulations for dry eye disease. The formulations, which will be packaged in a preservative-free bottle, are patent-pendi…

Read the full story

Monday, October 02, 2017 | Patents, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy Formulations

Imprimis Pharmaceuticals announced it has secured its first patent covering the company's Dropless Therapy formulations from the Australian Patent office, a division of IP Australia. Patent 201429…

Read the full story

Monday, September 11, 2017 | Corporate Lawsuits, Imprimis Pharmaceuticals

Imprimis Releases Statement Regarding Allergan Lawsuit

Imprimis Pharmaceuticals responded to a press release issued by Allergan regarding a lawsuit Allergan USA filed against Imprimis. A portion of the Imprimis statement reads: "Imprimis will aggr…

Read the full story

Thursday, July 27, 2017 | Milestones, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Patent-Pending Dropless and LessDrops Formulations Exceed One Million Patient Eyes Milestone

Imprimis Pharmaceuticals announced that its core patent-pending ophthalmic formulations have now served more than 1 million patient eyes. Imprimis first began offering ophthalmic solutions to physicia…

Read the full story

Thursday, May 04, 2017 | Product Releases, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Launches Simple Drops Combination Glaucoma Drops

Imprimis Pharmaceuticals announced the launch of its new patent-pending Simple Drops preservative-free glaucoma drops at the American Society of Cataract and Refractive Surgery (ASCRS) 2017 meeting in…

Read the full story

Tuesday, May 02, 2017 | Partnerships, Imprimis Pharmaceuticals, SightLife Surgical

Imprimis Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears

Imprimis Pharmaceuticals announced the signing of an exclusive strategic sales and marketing agreement. Under the agreement, SightLife Surgical will deploy their sales team to offer Imprimis’ Se…

Read the full story

Tuesday, April 18, 2017 | Partnerships, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals and Precision Lens Sign Agreement to Expand Imprimis’ Ophthalmic Portfolio Market

Imprimis Pharmaceuticals and Cameron Ehlen Group, d/b/a Precision Lens, announced the signing of a 3-year exclusive sales representation agreement. Under the agreement, Precision Lens will deploy a de…

Read the full story

Thursday, April 06, 2017 | Acquisitions/Mergers, Dry Eye, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Acquires Exclusive License to Patented Ophthalmic Formulation for Dry Eye Disease

Imprimis Pharmaceuticals announced that it has entered into an licensing agreement for the exclusive worldwide rights to Klarity, a patented ophthalmic topical solution and gel technology for patients…

Read the full story

Monday, March 20, 2017 | Cataract Surgery, Medical Studies, Imprimis Pharmaceuticals

Peer-Reviewed Paper Demonstrates the Benefits of Dropless Cataract Surgery

Imprimis Pharmaceuticals, an ophthalmology-focused pharmaceutical company, today announced the publication of a dropless therapy article in the peer-reviewed journal, Current Pharmaceutical Desig…

Read the full story

Thursday, February 16, 2017 | Product Releases, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility

Imprimis Pharmaceuticals announced that it has begun shipping its core sterile ophthalmic medications to select customers from its FDA-registered outsourcing facility without the need for a patient-sp…

Read the full story

Thursday, November 17, 2016 | Awards, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Ranked 12 on Deloitte’s 2016 Technology Fast 500 List of Fastest Growing Companies in North America

Imprimis Pharmaceuticals announced that it ranked 12 on Deloitte’s Technology Fast 500, an annual ranking of the fastest growing North American companies in the technology, media, telecommunicat…

Read the full story
Load More